Concentrated bone marrow aspirate (BMA) is a biologic concentrate derived from a patient’s own bone marrow, which represents 0.001-0.01% mononuclear cell concentration, red blood cell, immature myeloid precursors, granulocytes, and platelets. Gradient centrifugation is applied to BMA to separate mononuclear cells, (also known as BMAC) which can be used for the treatment of bone healing, cartilage repair and new blood vessel growth. The global bone marrow aspirate concentrates market was valued around US$ 130 Million and expected to reach over US$ 200 Million registering a growth rate more than 5.0% during forecast period of 2017 to 2025. Rising demand for technology driven solution, rapid economic growth, increasing disposable income, and growing awareness about stem cell-based treatment in the region have generated more opportunity, creating potential market from players in the U.S. and Europe.
Technological advancements in the bone marrow aspirate concentrates systems segment will drive growth of the segment in near future. Technological advancement is the development of a better device (in terms of BMAC preparation time, quantity of bone marrow stem cells separated, and cost) than the existing one. For instance, the ‘Harvest SmartPrep BMAC system’ is a point-of-care, easy-to-use system capable of separating a defined concentration of mononucleotide cells within 15 minutes. On the other hand, the existing centrifugation method is labor-intensive and time-consuming. It requires complex logistic considerations. Thus, technologically advanced BMAC solutions are anticipated to replace current procedure in near future. Emergence of biologic alternatives like PRP, BMAC and stem cell derived products are about to set a trend in the current market scenario as the orthobiologic procedures are considered to be less invasive and more effective as compared to traditional implantation procedures.
The bone marrow aspirate concentrates market is an emerging market. After 30 to 40 years of research, various stem cell treatments, technologies, and devices are in the development stage and approaching for commercialization. Thus, technological advancements and upcoming product launches in the market will drive market in near future.
Key players operate in the market include Terumo Corporation (Terumo BCT), Ranfac Corp., Arthrex, Inc., Globus Medical, Inc., Cesca Therapeutics Inc., MK Alliance Inc. (TotipotentSC), and Zimmer Biomet Holdings, Inc. the U.S. and Europe based key players are adopting strategic distribution agreement policies to expand geographical territory. In line with above strategy, in August 2017, Cesca Therapeutics Inc. announced a distribution agreement with Boyalife WSN Ltd., a China based company. Through this agreement, Boyalife WSN Ltd. will distribute Cesca’s innovative biobanking and point-of-care solutions in China, India, Singapore, and the Philippines. As India and China represent two of the fastest growing economies in the world, successful penetration of these regions can generate more market opportunity to the companies.